ABI-RA
Patients with RA diagnosis according to 2010 ACR/EULAR criteria and who were prescribed for the first time a BP among the TNF inhibitors adalimumab, infliximab (original product or biosimilar), etanercept, the anti-CD20 antibody rituximab, or the anti-IL6R antibody tocilizumab (administered SC or intravenously) as first-line or second-line therapy were recruited from March 3, 2014 to June 21, 2016. Patients who were not naive for the biotherapy they were given in the study were excluded.
- Project Title
- ABIRISK
- Project website
- http://www.abirisk.eu
- Primary Purpose
- Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients (ABI-RA)
- Study Types
- observational
- Description of Cohorts
- 229 patients (176 female, 53 male) diagnosed with RA.
- Informed Consent Given?
- True
- Multi-center Study?
- True
- Organisms
- Homo sapiens
- Number of subjects
- 229
- Diseases
- rheumatoid arthritis juvenile idiopathic arthritis
- Sample Sources
- tissue sample
- Type of Samples Collected
- plasma PBMCs DNA RNA
